Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $21M Series A (Aug 2025) led by Peak XV Partners with Endeavor Health Ventures and YC. Coding Copilot enables 90% faster chart coding. 5%+ revenue uplift, 43%+ fewer denials.
Arintra is an AI medical coding platform that autonomously codes clinical charts with no human intervention, delivering measurable improvements in coding accuracy and speed. The company raised $21 million in Series A financing in August 2025 led by Peak XV Partners (formerly Sequoia India/SEA), with Endeavor Health Ventures and Y Combinator as co-investors. The Coding Copilot enables medical coders to work 90% faster by surfacing recommended codes with supporting clinical documentation.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.